Search for Clinical Trial Results
Angiomatosis - 46 Studies Found
Status | Study |
Terminated |
Study Name: Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease Condition:
Date: 2009-11-16 Interventions: Drug: Avastin Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months |
Completed |
Study Name: Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 Condition:
|
Active, not recruiting |
Study Name: Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease Condition:
Date: 2000-06-06 |
Active, not recruiting |
Study Name: Von Hippel-Lindau Disease Genetic Epidemiology Study Condition:
Date: 1999-11-03 |
Completed |
Study Name: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Condition:
|
Active, not recruiting |
Study Name: Pazopanib in Von Hippel-Lindau (VHL) Syndrome Condition: Von Hippel-Lindau Syndrome Date: 2011-09-15 Interventions: Drug: Pazopanib 800 mg by mouth once daily for up to six, four week cycles. |
Terminated |
Study Name: TKI 258 in Von Hippel-Lindau Syndrome (VHL) Condition: Von Hippel-Lindau Syndrome Date: 2010-12-22 Interventions: Drug: Dovitinib 500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cy |
Terminated |
Study Name: Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome Condition: Von Hippel-Lindau Syndrome Date: 2008-05-06 Interventions: Drug: Sunitinib Malate Participants were expected to receive 9 months of sunitinib malate therapy admini |
Completed |
Study Name: Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Condition: Von Hippel-Lindau Syndrome Date: 2004-08-12 Interventions: Drug: Ranibizumab |
Recruiting |
Study Name: PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Condition:
|